Imatinib Qilu Pharma Spain

Imatinib, the active ingredient in Imatinib Qilu Pharma Spain, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Qilu Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, adhering to stringent quality standards and providing regulatory documentation to support import and clinical use through reliable logistics networks globally.

Imatinib is a tyrosine kinase inhibitor that targets specific molecular pathways in several hematologic and solid‑tumor cancers.

- Chronic myeloid leukemia (CML): reduces disease progression and improves long‑term survival by inhibiting the BCR‑ABL fusion protein in adult patients. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy by blocking BCR‑ABL signaling in lymphoid blasts. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth driven by activating mutations in c‑KIT or PDGFRα, providing disease control in patients with unresectable or metastatic disease.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset often occurring early in therapy. - Edema: swelling of the hands, feet or ankles. - Muscle cramps or pain: intermittent discomfort in limbs. - Fatigue or weakness: general tiredness affecting daily activities. - Diarrhea: loose stools that may be watery. - Rash: mild skin irritation or erythema. - Headache: mild to moderate head pain. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis that may require discontinuation. - Cardiac failure: reduced left ventricular function leading to symptoms of heart failure.

Before initiating Imatinib therapy, several safety considerations should be reviewed to minimize risks.

- Renal function: assess baseline creatinine clearance and monitor periodically in patients with renal impairment. - Hepatic function: obtain liver enzyme tests before treatment and repeat during therapy, especially in those with liver disease. - Cardiac risk: evaluate history of heart failure or reduced ejection fraction prior to starting therapy. - Drug interactions: review concomitant medications for CYP3A4 modulators and QT‑prolonging agents. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; limited data are available. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure and efficacy. - Antacids containing aluminum or magnesium hydroxide: decrease oral absorption if taken concurrently.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase imatinib levels, requiring monitoring for adverse effects. - QT‑prolonging agents (e.g., sotalol, amiodarone): additive risk of cardiac arrhythmias. - Warfarin: imatinib may enhance anticoagulant effect, necessitating INR monitoring.